secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001819790-25-000077
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M
----------------------------------------------------------------------------

- Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.
- Net loss of $25.1M ($0.64 diluted loss per share), improved from $35.7M loss ($1.01 per share) in Q1 2024.
- Cash, cash equivalents and marketable securities $407.9M as of March 31, 2025, bolstered by $134.8M equity offering.
- SG&A expenses $85.0M, up from $51.6M, driven by DTC advertising and commercial expansion.
- On track to initiate Phase 2 trial of TP-04 for Ocular Rosacea in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/0001819790-25-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/tars-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001819790-25-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer